NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and morphological abnormalities, protected against...
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% DZD8586 exhibited significant antitumor...
JBD's ARTCs Image-Quality Engine Goes Commercial, Elevating Full-Color MicroLED Waveguide AR Glasses to an Unprecedented Visual Standard
SHANGHAI, June 4, 2025 /PRNewswire/ -- As a global leader in MicroLED microdisplay technology, JBD has announced that its proprietary, system-level image-quality engine for waveguide AR Glasses—ARTCs—has been fully integrated into RayNeo's flagship...
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Fujitsu 1FINITY T900 lab trial validates reduced cost per bit for more sustainable, high-performance, high-capacity networking KAWASAKI, Japan, June 4, 2025 /PRNewswire/ -- Fujitsu Limited announced that Orange S.A. successfully completed a lab...
e-STORAGE's SolBank 3.0 Successfully Passes Large-Scale Fire Testing (LSFT)
KITCHENER, ON, June 3, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), has...
Self Storage Awards Asia Gala Dinner announces winners at Self Storage Expo Asia 2025
HONG KONG, June 3, 2025 /PRNewswire/ -- The Self Storage Association Asia announces the Self Storage Association Awards Asia 2025 winners in Tokyo. The Awards recognise Asia-wide and local excellence in self storage in customer service, the use of...
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating...
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer
SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025
NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946)...
O-RAN ALLIANCE Global PlugFest Spring 2025 Demonstrated Steady Evolution of the O-RAN Ecosystem
O-RAN ALLIANCE Global PlugFests focus on testing and integration to accelerate the development of O-RAN based products and solutions The O-RAN Global PlugFest Spring 2025 advanced O-RAN technology and procedures for testing, deployment and operation...